Glucocorticoids in Systemic Lupus Erythematosus. Ten Questions and Some Issues

Journal of Clinical Medicine

Florencia Vivero¹  MaríaCecilia Goizueta²  Guillermo Ruiz-Irastorza³  Alvaro Danza⁴  Adriana Carlomagno⁴  Maira Arias Saavedra⁵  Sabrina Porta⁵ 

[1] Autoimmune Disease Unit, Hospital Privado de Comunidad, Mar del Plata B7600, Argentina;Autoimmune Disease Unit, Sanatorio 9 de Julio, Tucumán T4000, Argentina;Autoimmune Diseases Research Unit, BioCruces Bizkaia Health Research Institute, Cruces Univeristy Hospital, 48903 Bizkaia, Spain;Department of Internal Medicine, Faculty of Medicine, Universidad de la República, Montevideo 11000, Uruguay;Rheumatology Department, Hospital JM Ramos Mejía, Buenos Aires 1221, Argentina;

关键词: systemic lupus erythematosus;    SLE;    prednisone;    methylprednisolone;    glucocorticoids;    mortality;   

DOI  :  10.3390/jcm9092709

来源: DOAJ

【 摘 要 】

Since the discovery of glucocorticoids (GCs), their important anti-inflammatory effect, rapid mechanism of action, low cost, and accessibility have made them one of the mainstays of treatment for Systemic lupus erythematosus (SLE). Although their use has allowed controlling the disease and reducing acute mortality in severe conditions, the implementation of a scheme based on high doses for long periods has inevitably been accompanied by an increase in adverse effects and infections, including long-term damage. The objective of this review is to answer some important questions that may arise from its use in daily clinical practice, and to propose a paradigm based on the use of methylprednisolone pulses followed by medium-low doses and a rapid decrease of prednisone.

【 授权许可】

Unknown